Anti-CD20/Anti-CD3 Bispecific Antibody MBS303

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific antibody and T-cell engager (TCE) targeting both the tumor-associated antigen (TAA) CD20 and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20/anti-CD3 bispecific antibody MBS303 binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. MBS303, composed of a 2:1 bispecific antibody structure, binds to CD20 with two arms and CD3 molecule with one arm to increase affinity with tumor cells and decrease the off-target toxicity of T-cells.

**Synonyms:** - Anti-CD20/CD3 Bispecific Antibody MBS303 - Anti-CD20/CD3 Monoclonal Antibody MBS303 - Anti-CD3/Anti-CD20 Monoclonal Antibody MBS303 - MB S303 - MB-S303 - MBS303 - T-cell Engager MBS303 - TCE MBS303